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MaOBJECTIVES The aim of this study was to evaluate chronic, transvenous, unilateral phrenic nerve stimulation to treat
central sleep apnea (CSA) in a prospective, multicenter, nonrandomized study.
BACKGROUND CSA occurs predominantly in patients with heart failure and increases the risk for morbidity and
mortality. Established therapies for CSA are lacking, and those available are limited by poor patient adherence.
METHODS Fifty-seven patients with CSA underwent baseline polysomnography followed by transvenous phrenic nerve
stimulation system implantation and follow-up. Feasibility was assessed by implantation success rate and therapy
delivery. Safety was evaluated by monitoring of device- and procedure-related adverse events. Efﬁcacy was evaluated
by changes in the apnea-hypopnea index at 3 months. Quality of life at 6 months was evaluated using a sleepiness
questionnaire, patient global assessment, and, in patients with heart failure at baseline, the Minnesota Living With
Heart Failure Questionnaire.
RESULTS The study met its primary end point, demonstrating a 55% reduction in apnea-hypopnea index from baseline
to 3 months (49.5  14.6 episodes/h vs. 22.4  13.6 episodes/h of sleep; p < 0.0001; 95% conﬁdence interval for
change: 32.3 to 21.9). Central apnea index, oxygenation, and arousals signiﬁcantly improved. Favorable effects on
quality of life and sleepiness were noted. In patients with heart failure, the Minnesota Living With Heart Failure Ques-
tionnaire score signiﬁcantly improved. Device- or procedure-related serious adverse events occurred in 26% of patients
through 6 months post therapy initiation, predominantly due to lead repositioning early in the study. Therapy was well
tolerated. Efﬁcacy was maintained at 6 months.
CONCLUSIONS Transvenous, unilateral phrenic nerve stimulation appears safe and effective for treating CSA. These
ﬁndings should be conﬁrmed in a prospective, randomized, controlled trial. (Chronic Evaluation of Respicardia Therapy;
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361respiratory muscle activity and airﬂow. Commonly
presenting as Cheyne-Stokes breathing, the CSA
breathing pattern is recognizable by cycles of deep,
rapid, crescendo-decrescendo breathing (hyperpnea),
followed by slower, shallower breathing (hypopnea)
or no breathing at all with no respiratory effort from
the diaphragm (apnea) (Figure 1). These repeated cy-
cles during sleep impart signiﬁcant cardiovascular
insults, including hypoxemia (11), sympathetic ner-
vous system activation (12), acute pulmonary and
systemic hypertension (11), and arrhythmias (1,13).
Each individual episode contributes a discrete hyp-
oxic episode and a release of norepinephrine (12).
As the cycle continues, these insults continue to
adversely affect the heart and contribute to the
downward cycle of heart failure.SEE PAGE 370Despite optimal therapy of underlying disorders
(e.g., heart failure), CSA persists in many patients.
Treatment for CSA has used existing approaches for
obstructive sleep apnea, most notably continuous
positive airway pressure (CPAP) therapy. Although
effective in treating obstructive sleep apnea, CPAP
failed to diminish morbidity and mortality in a large
trial of CSA, perhaps because of its failure to alleviateFIGURE 1 Central Sleep Apnea With Cheyne-Stokes Breathing
Selected channels of a polysomnogram of a patient with central sleep aCSA in some patients; however, survival
improved in patients whose CSA was sup-
pressed by CPAP (14–16). A major limitation
with the use of CPAP is patient nonadherence
(17). A new type of positive airway pressure
therapy, adaptive pressure support servo-
ventilation, has been introduced to treat pa-
tients with CSA and is currently undergoing
clinical evaluation. Early, small, non-
randomized studies of adaptive pressure
support servoventilation in patients with heart failure
demonstrated favorable effects on cardiac function
(18). However, patient adherence to this mask-based
therapy may still be suboptimal (19). A number of
other therapies, including nocturnal oxygen admin-
istration, theophylline, and acetazolamide, have been
evaluated to treat patients with CSA but are limited
either by lack of demonstrated long-term efﬁcacy or
potential side effects (5). Given the limited options
for treating CSA, there is clearly a need for alternative
therapeutic approaches.
An alternative approach to treating patients with
CSA has been investigated using unilateral, trans-
venous phrenic nerve stimulation to restore a physi-
ological breathing pattern throughout sleep. This
therapy stimulates the diaphragm during sleep topnea with Cheyne-Stokes breathing.
FIGURE 3 Implanted remede System
In this patient, the neurostimulator was implanted in the right
pectoral area. The right subclavian approach was used to place
the stimulation lead (A) in the left pericardiophrenic vein and to
place the sensing lead (B) in the azygos vein.
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ing. The use of phrenic nerve stimulation to regulate
breathing has a long history of providing respiratory
support in patients with respiratory paralysis from
high cervical spinal cord injury (20). Temporary,
transvenous, unilateral phrenic nerve stimulation has
recently been shown to result in a more regular
breathing pattern, fewer apneic events, improved
oxygen saturation, and increased end-tidal carbon
dioxide, without suppressing the intrinsic drive to
breathe in patients with CSA (21). In a subsequent
study, temporary unilateral phrenic nerve stimula-
tion therapy reduced central apnea events and
signiﬁcantly improved important sleep parameters
(22). A fully implantable system with transvenous
leads was designed for the long-term application of
transvenous phrenic nerve stimulation (The remede
System, Respicardia, Inc., Minnetonka, Minnesota).
This implantable system is automated and requires
no patient intervention to function, thus eliminating
patient nonadherence. The 6-month results of a study
evaluating the feasibility, safety, and efﬁcacy of this
system in a broad population of patients with CSA are
presented here.
METHODS
SYSTEM DESCRIPTION. The remede System consists
of a pulse generator, a stimulation lead, an optional
sensing lead, and an external programmer used to
adjust the settings on the pulse generator or to review
diagnostic data via telemetry (Figure 2). The remede
pulse generator, similar in size and appearance to aFIGURE 2 The remede System
The remede System consists of an implantable pulse generator
an implantable stimulation leads and an external system
programmer.standard pacemaker, is implanted in the right or
left pectoral region (Figure 3). The system uses a
transvenous lead implanted in the left pericardio-
phrenic or right brachiocephalic vein to provide
neurostimulation to the adjacent phrenic nerve,
resulting in diaphragmatic contraction. Previous
evaluation of stimulation of the phrenic nerve
demonstrated acute efﬁcacy of unilateral stimulation,
which resulted in bilateral contraction of the dia-
phragm (Respicardia, data on ﬁle). Sensing of respi-
ration is accomplished either by the stimulation lead
or a separate lead inserted in the azygos vein. Device-
based sensors detect patient position and activity,
aiding the device in determining appropriate therapy
delivery times per the algorithm described in
Figure 4. As shown in Figure 5, phrenic neuro-
stimulation enables the resumption of normal
breathing. By stabilizing carbon dioxide, the remede
System prevents apneic events and the subsequent
periods of rapid breathing. An example of stimulation
during sleep testing is shown in Figure 6.
STUDY OVERVIEW AND PATIENT POPULATION. This
was a prospective, international, multicenter, non-
randomized feasibility, safety, and efﬁcacy study of
patients with CSA before and after therapy, using
patients as their own controls. The study was con-
ducted under a U.S. Food and Drug Administration
investigational device exemption and registered with
ClinicalTrials.gov (NCT01124370). Safety oversight
was provided by an independent Data and Safety
Monitoring Board (DSMB). The authors had full access
FIGURE 4 Therapy Algorithm
The therapy algorithm used by The remede System to provide
phrenic nerve stimulation during sleep. The system uses time of
day, activity level, and body position (upright or recumbent) to
determine a potential sleeping state and therefore if stimulation
should occur. All of these parameters are adjustable to tailor
therapy to each patient’s speciﬁc sleep routine.
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363to study data and take full responsibility for the
accuracy and completeness of the reported ﬁndings.
Patients were eligible if they had apnea-hypopnea
index (AHI) values of at least 20 and at least one-half
of their events were of central origin per poly-
somnography (PSG). Patients were excluded if $20%
of their AHI was composed of obstructive apnea
events. Patients were required to be on stable, optimal
medical therapy for any comorbidity before enroll-
ment. Additional exclusion criteria included phrenic
nerve palsy, baseline hypoxia (oxygen saturation
<90% on room air), severe chronic obstructive pul-
monary disease, creatinine >2.5 mg/dl, and anycardiac procedure in the 3 months before the baseline
study. Ethics committees at participating centers
approved the study, and patients provided written
informed consent before study procedures.
STUDY PROCEDURES. Baseline sleep assessment.
Eligible patients underwent overnight, attended PSG
scored by a core laboratory (Registered Sleepers, Inc.,
Leicester, North Carolina) according to the 2007
American Association of Sleep Medicine guidelines
(23). Respiratory effort was measured by respiratory
inductive plethysmography, and airﬂow was assessed
using thermal and pressure transducers. Obstructive
apnea was deﬁned as the absence of airﬂow in the
presence of respiratory effort for >10 s. Central apnea
was deﬁned as the absence of respiratory effort and
airﬂow for >10 s. Mixed apnea was deﬁned as a
minimum of 3 respiratory efforts with absent inspi-
ratory effort at the beginning of the episode. Hypo-
pnea was deﬁned as a $30% reduction in airﬂow
lasting at least 10 s, associated with at least a 4%
decrease in arterial oxyhemoglobin saturation and
was not further classiﬁed. An electroencephalo-
graphic arousal was deﬁned as the appearance of
alpha waves or a shift to a greater frequency for at
least 3 s after at least 10 s of sleep. The AHI was
deﬁned as the number of episodes of apnea and
hypopnea per hour of sleep.
System implantat ion . After completing baseline
assessment, patients underwent implantation of the
remede System. Venous access was obtained via the
axillary or subclavian vein. On the basis of the pa-
tient’s anatomy and the implanting physician’s pref-
erence, the transvenous stimulation lead was placed
in either the left pericardiophrenic or the right bra-
chiocephalic vein. Differences in the size and angle of
the vessel and location and presence of valve struc-
tures may make lead placement variable for each
patient. Therefore, leads were available for both the
left pericardiophrenic vein and the right brachioce-
phalic vein. Response to neurostimulation was
assessed by external palpation of diaphragmatic
contraction and/or by observing movement of the
diaphragm during ﬂuoroscopy. An additional sensing
lead was placed in the azygos vein as necessary at the
time of implantation. All leads were secured to the
pectoralis muscle, connected to the remede neuro-
stimulator, and secured in a subcutaneous pocket in
the pectoral area.
After a 1-month healing period, patients under-
went PSG for therapy initiation. Therapy was pro-
grammed to begin when the patient was in a sleeping
position and at rest during normal sleep hours. Indi-
vidualized device settings, including therapy start
FIGURE 5 Graphical Representation of Phrenic Nerve Stimulation Delivered by the remede System During Sleep
Phrenic neurostimulation stimulates the diaphragm during sleep to stabilize gas exchange and maintain normal breathing. Typical pulse stimulation characteristics are
0.1 to 10 mA for 60 to 300 ms at 20 to 40 Hz.
FIGURE 6 Polysomnogram Demonstrating the Effect of Phrenic Nerve Stimulation
The tracing shows respiratory stabilization of a patient with central sleep apnea with Cheyne-Stokes respiration after transvenous, unilateral
phrenic nerve stimulation therapy.
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365and stop times and programmed maximal stimulation
parameter, were determined by interviewing the pa-
tient regarding sleep habits and then monitoring
response to overnight stimulation. Programmed
maximal stimulation parameter is the stimulation
setting that maximizes the reduction in AHI while
minimizing sleep disruptions.
Fol low-up v is i t s . Patients returned for follow-up at
1, 2, 3, and 6 months post therapy initiation. At the
1- and 2-month visits, patients were assessed for
therapeutic response and comfort. Stimulation set-
tings were adjusted if necessary. At the 3- and
6-month visits, patients were assessed for study end
points, and no changes were made to the program-
ming of the device during the end point study night.
PSG was performed at each of the 4 follow-up visits.
Patients will continue to be followed through 24
months as part of the ongoing study.
STUDY ENDPOINTS. The primary end point of the
study was change in the AHI after 3 months of ther-
apy. The expected reduction in the AHI due to treat-
ment with the remede System was 50%. This value
was chosen on the basis of an understanding that a
50% reduction in AHI is achievable, clinically mean-
ingful, and associated with a reduced risk for mor-
tality (9,24). Components of the AHI (i.e., central
apnea index, obstructive apnea index, mixed apnea
index, and hypopnea index) along with other stan-
dard sleep parameters were analyzed to characterize
the full impact of phrenic nerve stimulation therapy.
Secondary end points included the feasibility and
safety of transvenous, unilateral phrenic nerve stim-
ulation therapy. Feasibility was assessed by the lead
implantation success rate and ability to deliver ther-
apy. Safety was evaluated by continuous monitoring
of adverse events related to the device or therapy.
Additionally, changes in quality of life at 6 months
were evaluated using the Epworth Sleepiness Scale
(25), a patient global assessment (26), and the Min-
nesota Living With Heart Failure Questionnaire
(for patients with heart failure at baseline) (27).
STATISTICAL ANALYSIS. A minimal sample size of
40 patients was chosen on the basis of prior experi-
ence with transvenous, unilateral phrenic nerve
stimulation (22) and to provide reasonable conﬁdence
in the estimates of feasibility, safety, and efﬁcacy.
Baseline demographic and outcome results were
summarized using standard summary statistics for
continuous and categorical data. Differences in
outcome measures between baseline and 3 months
were tested with paired Student t tests. If there was
evidence of non-normality (Shapiro-Wilk test) in the
distribution of these paired outcome data, differenceswere tested with the nonparametric Wilcoxon signed
rank test.
The primary end point (AHI change from baseline at
3 months) was considered statistically signiﬁcant if
the p value was #0.05. Nominal p values associated
with other statistical tests are reported without
adjustment for multiple testing or assignment of sta-
tistical signiﬁcance levels. Differences among base-
line, 3 months, and 6 months were tested with a
repeated-measures analysis of variance. If there was
evidence of non-normality in the distribution of these
repeated measures, the differences across the 3 visits
were tested with the nonparametric Friedman test.
Statistical analyses were performed with SAS version 9
(SAS Institute Inc., Cary, North Carolina).
RESULTS
PATIENTS. Between June 2010 and August 2012, 57
patients were enrolled in the study (Figure 7). Of
the enrolled patients, 8 (14%) left the hospital
without implanted systems: 7 had anatomical issues
that prevented lead placement, and 1 had a severe
reaction to anesthesia resulting in dislodgement of
the stimulation lead. Before the 3-month follow-up
visit, 2 patients were withdrawn from the study: 1
for placement of a left ventricular assist device and
another after a mechanical fall resulting in system
explantation. The DSMB judged these 2 events as
unrelated to phrenic nerve stimulation therapy or
the system implantation procedure. Forty-seven
patients were available for end point assessment
at 3 months (Table 1). The mean baseline AHI was
in the severe range at 49.5  14.6 episodes/h.
Heart failure was the predominant etiology of
CSA in the patient population, followed by other
cardiac causes, chronic opiate use, atrial ﬁbrillation,
and idiopathic causes. Follow-up continued out to
24 months.
PRIMARY OUTCOME. At 3 months, there was a mean
reduction in AHI of 27.1  17.7 episodes/h (55%,
p < 0.0001) accompanied by a mean reduction in
the central apnea index of 23.4  15.3 episodes/h
(84%, p < 0.0001) (Table 2). The AHI reduction was
not different for stimulation of the right (mean
reduction 26.8  17.5) or left (mean reduction 27.3 
18.2) phrenic nerve. Signiﬁcant improvement in sleep
efﬁciency, rapid eye movement sleep, arousals, and
oxygenation also occurred. Two of 47 patients (4%)
were unable to complete valid PSG at 6 months but
did complete the ofﬁce visit. In the 44 patients
available for 6-month assessment, improvements in
sleep parameters were maintained (Table 3).
FIGURE 7 Patient Disposition
Flow diagram indicating progress of eligible patients through the study. LVAD ¼ left ventricular assist device; PSG ¼ polysomnography.
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System neurostimulator and stimulation lead were
successfully implanted in 49 of 57 enrolled pa-
tients (86%). Of the 47 patients who reached the
3-month primary and secondary study end point
analyses, 29 (61%) had the lead implanted in the left
pericardiophrenic vein and 18 (39%) in the right
brachiocephalic vein. In 37 of 47 patients (79%), a
sensing lead was implanted in the azygos vein
to sense respiration. After implantation, 11 of 47
patients (23%) required lead repositioning, and an
additional patient had a lead dislodgement and was
unable to have the lead repositioned, resulting in
explantation. The majority (8 of 12) of cases in
which repositioning of the stimulation lead was
required occurred early in the study, when only the
left pericardiophrenic stimulation lead was available
for implantation. Variable venous anatomy made
implanting a lead securely in the left pericardio-
phrenic vein difﬁcult in some cases, and subse-
quently a lead designed for the right brachiocephalic
vein was introduced. This new lead and implanta-
tion location, along with improved operator experi-
ence with the left pericardiophrenic lead, resulted in
a ﬁrst-attempt implantation success rate of 100% forthe last 20 patients enrolled in the study (15 left
pericardiophrenic vein leads, 5 right brachiocephalic
vein leads). During the course of the study, none of
the patients requested that therapy be discontinued.
Patients received 5.4  1.2 h of therapy during
5.8  1.2 h of sleep every night, on the basis of the
algorithm in Figure 4.
The presence of additional leads in the vasculature
did not result in failure to implant the remede Sys-
tem. In addition, there was no difference in compli-
cations or the length of the procedure in patients with
successful implants.
Safety . One of 47 patients (2%) died between
the 3- and 6-month follow-up visits because of end-
stage heart failure. The DSMB adjudicated this
death as not related to the procedure or to phrenic
nerve stimulation therapy. Three of 47 patients
(6%) were adjudicated by the DSMB as having
serious adverse events related to the device, im-
plantation procedure, or therapy but not related to
lead dislodgement. Two patients had serious adverse
events (hematoma and migraine) related to the im-
plantation procedure. An additional patient had a
serious adverse event on the night when therapy was
originally initiated, and the stimulation sensation
TABLE 1 Baseline Patient Demographics (n ¼ 47)
Age, yrs 65.9  9.6
Body mass index, kg/m2 29.3  4.4
Men 89%
Atrial ﬁbrillation 30%
AHI, episodes/h of sleep 50  15
CAI, episodes/h of sleep 28  14
OAI, episodes/h of sleep 3  3
History of hypertension 74%
CSA etiology
Atrial ﬁbrillation 2%
Opiate use 4%
Idiopathic 2%
Other cardiac 13%
Heart failure 79%
New York Heart Association functional class
I 9%
II 47%
III 21%
IV 2%
Heart failure with ejection fraction >40% 9%
Coronary artery disease 66%
Systolic blood pressure, mm Hg 123  21
Diastolic blood pressure, mm Hg 73  11
Creatinine, mg/dl 1.2  0.4
Ejection fraction 30.5  11.6
Concomitant cardiac device 53%
Cardiac resynchronization þ deﬁbrillation device 19%
Implantable cardioverter-deﬁbrillator 28%
Pacemaker 6%
Medications in patients with heart failure and
reduced ejection fraction (n ¼ 31)
Aldosterone antagonist 48%
Beta-blocker 100%
ACE inhibitor or ARB 100%
Values are mean  SD or %.
ACE ¼ angiotensin-converting enzyme; AHI ¼ apnea-hypopnea index; ARB ¼
angiotensin II receptor blocker; CAI ¼ central apnea index; CSA ¼ central sleep
apnea; OAI ¼ obstructive apnea index.
TABLE 2 Effects on Sleep-Disordered Breathing Parameters at 3 Mon
Parameter Baseline 3 Month
AHI, episodes/h of sleep 49.5  14.6 22.4  13.6
CAI, episodes/h of sleep 28.0  14.2 4.7  8.6
OAI, episodes/h of sleep 3.0  2.9 3.9  4.7
MAI, episodes/h of sleep 3.4  4.5 0.3  0.6
HI, episodes/h of sleep 15.1  12.1 13.5  9.0
ODI4, episodes/h of sleep 45.2  18.7 21.6  13.7
Arousal index, episodes/h of sleep 36.2  18.8 23.7  10.6
Sleep efﬁciency, % 68.3  17.2 76.6  15.4
REM sleep, % 11.1  6.8 15.6  8.2
Values are mean  SD. *Paired Student t test. †Wilcoxon signed rank test.
CI ¼ conﬁdence interval; HI ¼ hypopnea index; MAI ¼ mixed apnea index; ODI4 ¼ 4
in Table 1.
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367was associated with atypical chest discomfort.
Therapy was reinitiated on the following night
without further discomfort.
Qual i ty of l i fe . Sleepiness was alleviated, as evi-
denced by a reduction in the mean Epworth Sleepi-
ness Scale score in patients at 6 months (from 8.0 
3.9 to 6.1  4.6, p ¼ 0.0034) and in patients with
Epworth Sleepiness Scale scores >10 at baseline
(from 12.4  1.9 to 8.5  5.2, p ¼ 0.0023). All 46 pa-
tients completed the 6-month patient global assess-
ment, which asked the patient to reply, on a 7-point
scale, to the question “How do you feel today as
compared to how you felt before having your device
implanted?” (27). Twelve (26%) reported marked
improvement, 14 (30%) moderate improvement,
9 (20%) mild improvement, and 10 (22%) no change,
and 1 (2%) reported being slightly worse. No patients
reported being moderately worse or markedly worse.
The Minnesota Living With Heart Failure Question-
naire, completed by the 36 patients with heart failure
at 6 months, also showed improvement by an average
of 10 points (p ¼ 0.0009; 95% conﬁdence interval:
16 to 4).
DISCUSSION
The present study demonstrates the feasibility,
safety, and efﬁcacy of long-term, transvenous, uni-
lateral phrenic nerve stimulation as a treatment for
patients with CSA using an implantable system.
Results showed improvement in AHI, central apnea
index, arousals, sleep efﬁciency, and rapid eye
movement sleep after 3 months of treatment. These
improvements were sustained at 6 months and were
accompanied by alleviation of both sleepiness
and heart failure symptoms. The mean obstructive
apnea index was unchanged, suggesting that therapyths With the remede System (n ¼ 47)
s Difference (95% CI) p Value
27.1  17.7 (32.3 to 21.9) <0.0001*
23.4  15.3 (27.8 to 18.9) <0.0001*
0.9  5.4 (0.7 to 2.4) 0.2816*
 1.0 3.0  4.5 (4.4 to 1.7) <0.0001†
1.5  14.8 (5.9 to 2.8) 0.4809*
23.7  21.2 (29.9 to 17.4) <0.0001*
12.5  16.9 (17.5 to 7.6) <0.0001*
8.4  20.2 (2.4 to 14.3) 0.0066*
4.5  11.2 (1.2 to 7.8) 0.0086*
% oxygen desaturation index; REM ¼ rapid eye movement; other abbreviations as
TABLE 3 Effects on Sleep Parameters at 6 Months With the remede System (n ¼ 44)
Parameter Baseline 3 Months 6 Months p Value
AHI, episodes/h of sleep 49.4  14.9 22.8  13.6 23.3  13.3 #0.0001*
CAI, episodes/hr of sleep 28.1  14.7 5.0  8.8 4.5  7.2 <0.0001*
OAI, episodes/hr of sleep 3.0  2.8 3.9  4.8 3.8  5.2 0.0223†
MAI, episodes/h of sleep 3.0  3.7 0.3  0.6 0.6  1.5 <0.0002*
HI, episodes/h of sleep 15.4  12.4 13.5  9.0 14.4  8.3 0.0179†
ODI4, episodes/hr of sleep 46.0  18.8 22.0  13.8 22.9  13.3 <0.0001*
Arousal index, episodes/h of sleep 35.5  18.4 23.4  10.9 24.7  12.3 <0.0001*
Sleep efﬁciency, % 69.3  16.8 76.9  15.6 81.4  12.5 <0.0001*
REM sleep, % 11.2  6.3 16.2  8.1 17.4  6.9 <0.0001*
Values are mean  SD. *Repeated-measures analysis of variance. †Friedman test.
Abbreviations as in Tables 1 and 2.
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368did not induce or contribute to upper airway
obstruction.
Results from the patient global assessment showed
that the majority of patients experienced alleviation
of symptoms after 6 months of phrenic nerve stimu-
lation therapy. Patients with heart failure showed
signiﬁcant improvement in Minnesota Living With
Heart Failure Questionnaire score at 6 months, com-
parable to that seen with cardiac resynchronization
therapy (28). If this ﬁnding is conﬁrmed in future
randomized controlled trials, treatment with the
remede System may offer signiﬁcant symptomatic
alleviation for this patient group.
This study represents the largest cohort of subjects
to be implanted with The remede System to date with
the intent to determine the long-term (3-month)
feasibility of pacing the phrenic nerve while assessing
safety and efﬁcacy. Although quality-of-life in-
dicators are subject to inﬂuence, especially in an
unblinded, open-label, uncontrolled study, the AHI is
an unbiased end point lending credibility to the sta-
tistically signiﬁcant reduction achieved. Reduction in
AHI has been shown to improve outcomes for patients
with obstructive sleep apnea, and similar ﬁndings
have been seen in small studies of CSA. Furthermore,
it has been demonstrated that mortality is related
to the severity of the AHI (9,24), suggesting that a
reduction in AHI by the remede System may reduce
the risk for mortality.
System implantation was successful in 86% of
patients, which is similar to that seen in early trials
of new transvenous lead technologies (e.g., cardiac
resynchronization therapy) (29). The success rate
improved throughout the study, particularly with
the introduction of a right brachiocephalic vein lead
better suited for some anatomies and improved im-
plantation techniques. Twenty-six percent of pa-
tients had serious adverse events related to thedevice or procedure. Although this number may
initially appear high, it is similar to other newly
introduced cardiac devices, such as cardiac
resynchronization therapy, at this stage of develop-
ment (29).
Beneﬁt and risk need to be considered together.
The beneﬁt to the patient from this signiﬁcant
reduction in AHI is clinically meaningful and associ-
ated with improved symptoms. The adverse event
proﬁle noted is representative of early experience
with the implantation technique, technology, and
tools available to the implanter. The proﬁle is similar
to early development of cardiac resynchronization
implantation techniques and tools. Coupled with
increased experience, improvements made to the
implantation tools and techniques are expected to
reduce the rate of device- and procedure-related
adverse events in the future. The beneﬁt of AHI
improvement demonstrated by the remede System
is clinically meaningful and outweighs the risk for
adverse events seen in this trial.
Given the prevalence of CSA and its association
with increased morbidity and mortality in certain
clinical disorders, there is a need for better therapies.
The pathophysiologic mechanisms responsible for the
deleterious effects of CSA are now increasingly un-
derstood. Cyclical episodes of apnea and arousal are
associated with hypoxia and norepinephrine release,
which may contribute to myocardial ischemia and
ﬁbrosis, progressive worsening of cardiac function,
and increased risk for atrial and ventricular arrhyth-
mias (1,13,30). Sleep apnea also induces a proin-
ﬂammatory milieu, and it has been associated with
increased risk for dementia and worsening of diabetes
control (30).
The present study is limited by its size, the lack of a
parallel control arm, and the diversity of the patient
population. Because no parallel control arm was
included, some of the effect could be due to regres-
sion to the mean. However, longitudinal studies of
CSA have not shown signiﬁcant improvements in
sleep-disordered breathing parameters without ef-
fective treatment (15). Thus, the efﬁcacy seen in the
present study likely represents a treatment rather
than a placebo effect.
In summary, transvenous, unilateral phrenic nerve
stimulation appears to be a safe and effective approach
for the treatment of CSA. By directly stimulating the
phrenic nerve, this approach may restore a more nat-
ural breathing pattern, resulting in additional im-
provements in cardiac symptoms, sympathetic surges,
and outcomes. The present observations should
be conﬁrmed in a larger prospective, randomized,
controlled trial.
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